HOME >> MEDICINE >> NEWS
Biomolecule studied for medical uses

DURHAM, N.C. -- Duke University Chemistry Department researchers are creating unique polymers out of naturally occurring building blocks that don't provoke immune reactions and in some cases also biodegrade in the body. The tree-like, globular-shaped substances are being evaluated for a variety of medical uses.

Called biodendrimers, these structures are prepared by systematically reacting acids with alcohols to form what chemists call "esters." The results are branching molecular chains with finger-like ends that can form sticky and tenacious links with other substances.

These characteristics make them "ideal candidates for medical and tissue engineering applications," said Mark Grinstaff, the assistant chemistry professor who heads the Duke team. One potential application, which Duke Medical Center eye researchers are beginning to test, is a glue that could "close a wound and then be dissolved as new tissue grows in to repair the wound site," he added in an interview.

"It could really potentially change the way we do corneal surgery," added Dr. Terry Kim, associate director of the Corneal and Refractive Surgery Service at the Duke Eye Center and a medical center assistant professor of ophthalmology.

Another possibility, which biomedical researchers at Duke's Pratt School of Engineering have also started investigating, would be using such biodendrimers as scaffolding to help induce cells to repair damaged human joints.

"Biodendrimers appear to interact with cells in completely novel manners," said Lori Setton, assistant professor and Harold L. Yoh Faculty Scholar in the Pratt School's Department of Biomedical Engineering. Because of its promise, Grinstaff's research just received $250,000 in funding from the Johnson & Johnson Focused Giving program, established to stimulate exploration in medical science. Other funding sources include the Pew, Sloan and Dreyfus foundations.

In a spring 2001 issue of the Journal of the Americ
'"/>

Contact: Monte Basgall
monte.basgall@duke.edu
919-681-8057
Duke University
30-Aug-2001


Page: 1 2 3 4

Related medicine news :

1. Technology that could double the effectiveness of cancer drugs studied at Yale
2. New global trials help to make FOSRENOL(R) the most extensively studied modern phosphate binder
3. Mind-body connection in placebo surgery trial studied by University of Denver researcher
4. Possible brain cancer-air pollution link to be studied
5. Investigational mesh jackets studied as an experimental therapy for heart failure
6. Venlafaxine XR, first SNRI studied for social anxiety disorder
7. New pathway for treating hypertension-related kidney failure studied
8. Intensification therapy studied in head and neck cancer
9. Chronic disease: the overlooked & understudied epidemic
10. Advertising by academic medical centers may risk eroding public trust, says study
11. NIH state-of-the-science panel calls for demedicalization of menopause

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biomolecule studied for medical uses

(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Washington, D.C. (PRWEB) October 22, 2014 With ... November, a national survey by the American Institutes for Research ... they know how to use health insurance, but 42 percent ... review a plan’s details before signing up for coverage. , ... literacy, with only 20 percent able to calculate correctly how ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Losing Weight Your Body’s ... is staring you in the face, it certainly can be ... do your body an extra favor by doing it the ... crash diets. Instead, listen to your body, exercise regularly, and ... is essential to losing weight; you need to exercise more ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)...  PneumRx, Inc. ( www.pneumrx.com ), a leader in ... enrollment in their RENEW Study, nearly 3 months ahead ... IDE pivotal trial for the PneumRx RePneu Coil System, ... anticipated that the study, which began enrolling subjects in ... end of 2014 to enroll 315 patients.  Instead, enrollment ...
(Date:10/20/2014)... 2014  Indianapolis interventional medical device maker ... -based 3D visualization leader Synaptive Medical ... Annual Meeting that they have joined forces to ... collaboration is the first of its kind and ... outcomes. NICO,s BrainPath® interventional access technology and Synaptive,s ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
Cached News: